Will Merck’s P2X3 Receptor Antagonist for Chronic Refractory Cough Treatment Be Able to Turn FDA’s Nay Into Yea?

Infectious Diseases

Biosurgery: Advancing Medicine through Biologic...

In recent years, the healthcare and medical devices market has undergone a remarkable transformation, largely fueled by advancements in technology and growth in innovation. One of the major standou...

Sep 13, 2023

Pharma News for Nexcella, Janssen, Alentis
FDA Approves BMS’s Reblozyl for MDS; FDA Awards Orphan Drug Designation to NXC-201; Janssen Submits Supplemental NDA for Full Approval of BALVERSA; FDA Grants Fast Track Status to ALE.C04; FDA Orphan Drug Designation to Faron’s Bexmarilimab; FDA Clears IND Application for AHB-137

FDA Approves Bristol Myers Squibb’s Reblozyl as First-Line Treatment of Anemia in Adults with Lower-Risk MDS Who May Require Transfusions Bristol Myers Squibb announced that the Food and Drug Administration (FDA) has approved Reblozyl® (luspatercept-aamt) for the treatment of anemia in adult patients with very l...

Find More
Pharma News for Biogen, Astellas, Ascentage
FDA Approves ZURZUVAE for Postpartum Depression; Astellas Drug Acquired in $5.9B Deal Wins FDA Approval; FDA Clearance to Phase III Study of Lisaftoclax; FDA Issues CRL to BLA Resubmission for Remestemcel-L; Bavarian Nordic Updated on its Chikungunya Virus Vaccine; FDA Orphan Drug Designation to ABM-1310

FDA Approves ZURZUVAE, the First and Only Oral Treatment Approved for Women with Postpartum Depression Biogen Inc. and Sage Therapeutics, Inc. announced that the FDA has approved ZURZUVAE (zuranolone) 50 mg for individuals with postpartum depression (PPD). ZURZUVAE is the first and only 14-day oral, once-daily t...

Find More
Herbal Medicine Market
What Is Herbal Medicine? A Comprehensive Exploration of Nature’s Healing Gift

Herbal medicine, also known as traditional medicine, botanical medicine, herbalism, or natural medicine, is an ancient healing practice that dates back thousands of years. Herbal Medicine is part of the alternative medicine system, which encompassed several other forms of medical systems. As per the WHO, “Tradition...

Find More

More Views & Analysis

Omega-3 Products Market Outlook
Evaluating the Rising Demand & the Market Potential of the Omega-3 Products

In recent years, the demand for Omega-3 Products has risen exponentially. Omega-3 fatty acids are also referred to as Polyunsaturated fatty acids and work in the body to lower triglycerides, reduce inflammation, and improve heart health, among several other functions. As per DelveInsight’s latest assessment, the gl...

Find More

Pharma News and Updates for GSK, Gilead, ProMIS, Nucleix, PharmaTher, Vedanta Biosciences
FDA Approves GSK’s Arexvy for RSV; CHMP’s Opinion on Gilead’s Hepcludex® for HDV; FDA Clearance to ProMIS’s IND Application for PMN310; FDA Grants 501K Clearance to Bladder EpiCheck; PharmaTher Submits Fast Track Application for Ketarx to US FDA; Fast Track Designation to Vedanta Biosciences’ VE303

FDA Approves GSK’s Arexvy, the First RSV Vaccine for Older Adults GSK plc stated that the US Food and Drug Administration (FDA) has approved Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by a respiratory syncytial virus (RSV) in peopl...

Find More

gsk-respiratory-syncytial-virus-vaccine
GSK Is All Set To Launch Respiratory Syncytial Virus Vaccine… Now Who’s Next?

Infections due to respiratory syncytial virus (RSV) have seriously troubled drug makers for decades and the need for a vaccine was on since the 1960s. According to the assessment done by DelveInsight on the latest published “Respiratory Syncytial Virus Epidemiology Report,” it is estimated to affect approximately 5...

Find More

emerging-vaccines-for-respiratory-syncytial-virus-treatment
Respiratory Syncytial Virus Treatment Market: A Complex Space Worth Billions!

Respiratory syncytial virus is estimated to affect approximately 5 million cases this year in the United States and 2.5 million RSV cases in the EU4 countries and the United Kingdom. As per Delveinsight analysis on the latest published “Respiratory Syncytial Virus Epidemiology Report,” the US comprised ~70%, ~27%, ...

Find More

epstein-barr-virus-ebv-treatment-outlook
Changing Landscape of EBV-associated Diseases Treatment: Is T-cell Immunotherapy the Answer?

Epstein–Barr virus (EBV), also known as human herpesvirus 4 (HHV-4), was discovered in the 1960s as an inescapable virus that infects almost 95% of the world’s population and causes nearly 1% of all cancers. Besides, the virus is a leading cause of infectious mononucleosis (IM) and is associated with different subt...

Find More

Biologics in the Nasal Polyposis Treatment Market
Biologics Spark Market Interest In The Nasal Polyposis Treatment Space

A highly prevalent condition, Nasal polyps are benign growths in the mucosa of the nose that blocks the nasal passageway, reducing the quality of life (QoL), causing hyposmia or anosmia and sleep disturbances in those affected. Often associated with chronic nasal inflammation and conditions like asthma, these are a...

Find More

Myocardial Infarction
Myocardial Infarction...

Myocardial infarction (MI), colloquially known as “heart attack” is caused by decreased or compl.....

Find More
Acute Ischemic Stroke (AIS)
Acute Ischemic Stroke (AI...

Acute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, whic.....

Find More
Rheumatoid Arthritis
Rheumatoid Arthritis...

Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive an.....

Find More